Johnson & Johnson delivers quarterly dividends backed by steady cash flows from its consumer health, pharmaceuticals and medical devices segments. The assessment examines J&J’s current yield, historical payout increases and conservative payout ratio to evaluate its reliability as an income-generating holding.